Dr. Gelmann is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
177 Fort Washington Ave
# 6N435
New York, NY 10032Phone+1 212-305-8602
Education & Training
University of ChicagoResidency, Internal Medicine, 1976 - 1978
Stanford University School of MedicineClass of 1976
Certifications & Licensure
CA State Medical License 1979 - Present
AZ State Medical License 2018 - 2026
MD State Medical License 1978 - 2026
NY State Medical License 2007 - 2026
DC State Medical License 1988 - 2024
IL State Medical License 1977 - 1987- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Top Doctors: New York Metro Area Castle Connolly, 2009-2014
- America's Top Doctors Castle Connolly, 2006-2014
- New York Magazine: Top Doctors Castle Connolly, 2010-2013
- Join now to see all
Clinical Trials
- Nitrocamptothecin in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy Start of enrollment: 2000 May 01
- S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer Start of enrollment: 2013 Mar 08
Publications & Presentations
PubMed
- 413 citationsThe Ubiquitin-Proteasome Pathway and Its Role in CancerAparna Mani, Edward P. Gelmann
Journal of Clinical Oncology. 2005-07-20 - 46 citationsv-rasH expression confers hormone-independent in vitro growth to LNCaP prostate carcinoma cells.H. James Voeller, George Wilding, Edward P. Gelmann
Molecular Endocrinology. 1991-02-01 - 81 citationsQuality of Life and Trial Adherence Among Participants in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening TrialKathryn L. Taylor, Rebecca A. Shelby, Edward P. Gelmann, Colleen McGuire
Journal of the National Cancer Institute. 2004-07-21
Press Mentions
Targeting the Engine Room of the Cancer CellJune 19th, 2018
Targeting the Engine Room of the Cancer CellJune 18th, 2018
Grant Support
- Protocol Specific Research ResourceNational Cancer Institute2008–2011
- Crmo- Clinical Research Management OfficeNational Cancer Institute2008–2011
- Genetic Polymorphism In Prostate CancerNational Institute Of Environmental Health Sciences2007
- Cancer And Leukemia Group BNational Cancer Institute2003–2006
- Genetic Polymorphism In Prostate CancerNational Institute Of Environmental Health Sciences1999–2006
- Beta Catenin In Prostate CancerNational Cancer Institute2002–2005
- Prostate, Lung, Colorectal &Ovarian Cancer Screening Tria-261925522National Cancer Institute2003
- Cancer And Acute Leukemia Group B (CALGB) Inst GrantNational Cancer Institute2001–2002
- Beta Catenin In Prostate CancerNational Cancer Institute2000–2001
- Apoptosis In Prostate CancerNational Cancer Institute1999–2001
- Prostate, Lung, Colorectal &Ovarian CancerDivision Of Cancer Prevention And Control1994–2000
- Nkx31 In Prostate CancerNational Cancer Institute1998–1999
- Markers For Malignant Progression In Prostate CancerNational Cancer Institute1992–1996
- Specialized PGM Of Research Excellence/Prostate CancerNational Cancer Institute1992–1994
- Molecular Mechanisms For Prostate Cancer Cell GrowthNational Cancer Institute1990–1992
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
